NEW YORK (GenomeWeb News) – Fluxion Biosciences today announced a distribution deal for EMD Millipore's Precision range of ion channel cell lines.
The deal combines Fluxion's IonFlux automated patch clamp instrumentation with EMD Millipore's ion channel cell lines, which Fluxion said are the industry standard for electrophysiology screening and profiling.
As part of the non-exclusive deal, Fluxion will provide its IonFlux customers with cell lines that are performance validated on the IonFlux automated patch clamp platform.
Financial and other terms of the agreement were not disclosed.
By automating the "patch clamp" technique, the IonFlux platform allows the ion channel drug target class to be screened in "a physiologically relevant context," Fluxion said, adding that companies such as Pfizer, Novartis, Genentech, and Sanofi-Aventis have adopted the system.
Umesh Patel, director of Lead Discovery at EMD Millipore, said in a statement, "Our goal is to provide validated cells lines that deliver the highest performance across the broadest range of applications. Providing cells through Fluxion that have been fully validated on their IonFlux system is a natural extension of these goals, and it provides our customers with a complete, one-stop solution for their electrophysiology screening and profiling needs."